The role of interleukin 1 in growth and metastasis of human cancer xenografts
- PMID: 16489061
- DOI: 10.1158/1078-0432.CCR-05-1603
The role of interleukin 1 in growth and metastasis of human cancer xenografts
Abstract
Background: Interleukin 1 (IL-1) is a pluripotent cytokine that promotes angiogenesis, tumor growth, and metastasis in experimental models; its presence in some human cancers is associated with aggressive tumor biology. The purpose of these studies was to characterize the role of IL-1 in human cancers and determine if inhibition of IL-1 via its receptor antagonist, IL-1Ra, alters tumor growth and metastatic potential.
Methods: IL-1 mRNA or protein levels were determined in clinical tumor samples, cancer cell lines, and xenografts using quantitative reverse transcription-PCR or ELISA. Biological activity of tumor-derived IL-1 protein was shown via induction of permeability across endothelial cell monolayers. The effects of recombinant IL-1Ra on tumor lines in culture (cell proliferation and IL-8 secretion) and in xenograft models (tumor growth, metastatic potential, and intratumoral levels of IL-8 and VEGF) were characterized. The effects of IL-1Ra-mediated regression of xenograft growth on angiogenic proteins (IL-8 and VEGF) were evaluated in an IL-1-producing melanoma (SMEL) xenograft model.
Results: IL-1 mRNA was highly expressed in more than half of all tested metastatic human tumor specimens including non-small-cell lung carcinoma, colorectal adenocarcinoma, and melanoma tumor samples. Constitutive IL-1 mRNA expression was identified in several cancer cell lines; tumor supernatant from these cell lines produced a significant increase in endothelial cell monolayer permeability, a hallmark event in early angiogenesis, in an IL-1-dependent manner. Moreover, systemic recombinant IL-1Ra resulted in significant inhibition of xenograft growth and neovessel density of IL-1-producing, but not non-IL-1-producing, tumor cell lines. Subsequent analysis of SMEL, a melanoma cell line with constitutive IL-1 production, showed that neither exogenous IL-1 nor IL-1Ra altered tumor cell proliferation rates in vitro. Gene expression analyses of IL-1Ra-treated SMEL xenografts showed a >3-fold down-regulation of 100 genes compared with control including a marked down-regulation of IL-8 and VEGF.
Conclusions: These data show that the IL-1 gene is frequently expressed in metastases from patients with several types of human cancers. IL-1Ra inhibits xenograft growth in IL-1-producing tumors but has no direct antiproliferative effects in vitro; decreased tumor levels of IL-8 and VEGF may be an early surrogate of IL-1Ra-mediated antitumor activity. IL-1Ra may have a role alone or with other agents in the treatment of human cancers.
Similar articles
-
Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice.Cancer Res. 2003 Sep 15;63(18):5957-61. Cancer Res. 2003. PMID: 14522922
-
Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo.Anticancer Res. 1996 Jan-Feb;16(1):437-41. Anticancer Res. 1996. PMID: 8615650
-
The intracellular IL-1 receptor antagonist alters IL-1-inducible gene expression without blocking exogenous signaling by IL-1 beta.J Immunol. 1995 Nov 1;155(9):4467-75. J Immunol. 1995. PMID: 7594609
-
Interleukin-1.Cytokine Growth Factor Rev. 1997 Dec;8(4):253-65. doi: 10.1016/s1359-6101(97)00023-3. Cytokine Growth Factor Rev. 1997. PMID: 9620641 Review.
-
The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism.J Atheroscler Thromb. 2006 Feb;13(1):21-30. doi: 10.5551/jat.13.21. J Atheroscler Thromb. 2006. PMID: 16505588 Review.
Cited by
-
Targeting cytokine and chemokine signaling pathways for cancer therapy.Signal Transduct Target Ther. 2024 Jul 22;9(1):176. doi: 10.1038/s41392-024-01868-3. Signal Transduct Target Ther. 2024. PMID: 39034318 Free PMC article. Review.
-
Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells.Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul 11. doi: 10.1007/s00210-024-03286-2. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38990306
-
The role of bidirectional communication between the adipokines and the endogenous opioid system in an experimental mouse model of colitis-associated colorectal cancer.Pharmacol Rep. 2024 Feb;76(1):112-126. doi: 10.1007/s43440-023-00566-1. Epub 2024 Jan 18. Pharmacol Rep. 2024. PMID: 38236555
-
Risk factors analysis and survival prediction model establishment of patients with lung adenocarcinoma based on different pyroptosis-related gene subtypes.Eur J Med Res. 2023 Dec 18;28(1):601. doi: 10.1186/s40001-023-01581-x. Eur J Med Res. 2023. PMID: 38111060 Free PMC article.
-
Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas.Heliyon. 2023 Mar 28;9(4):e14960. doi: 10.1016/j.heliyon.2023.e14960. eCollection 2023 Apr. Heliyon. 2023. PMID: 37025835 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources